Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,177,356
  • Shares Outstanding, K 196,709
  • Annual Sales, $ 13,453 M
  • Annual Income, $ 4,431 M
  • 36-Month Beta 1.13
  • Price/Sales 4.90
  • Price/Cash Flow 10.56
  • Price/Book 5.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 6.90
  • Number of Estimates 24
  • High Estimate 7.45
  • Low Estimate 6.39
  • Prior Year 6.05
  • Growth Rate Est. (year over year) +14.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
305.45 +5.66%
on 02/08/19
344.00 -6.18%
on 01/23/19
-16.23 (-4.79%)
since 01/22/19
3-Month
278.46 +15.90%
on 12/24/18
344.00 -6.18%
on 01/23/19
+7.17 (+2.27%)
since 11/21/18
52-Week
249.17 +29.52%
on 04/24/18
388.67 -16.97%
on 07/25/18
+37.92 (+13.31%)
since 02/22/18

Most Recent Stories

More News
Biogen Inc Falls 3.60% on Heavy Volume: Watch For Potential Rebound

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $322.64 to a high of $331.00. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $324.71...

BIIB : 323.79 (+0.82%)
AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review

AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.

NVS : 90.59 (+0.09%)
ABBV : 79.77 (+1.30%)
AMGN : 186.94 (+0.78%)
BIIB : 323.79 (+0.82%)
Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

CELG : 88.95 (+0.34%)
LLY : 123.94 (+0.99%)
ALKS : 33.16 (+1.81%)
BIIB : 323.79 (+0.82%)
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

IBB : 110.33 (+1.08%)
FBT : 143.92 (+0.92%)
BBH : 127.23 (+0.95%)
GILD : 65.56 (+0.02%)
AMGN : 186.94 (+0.78%)
BIIB : 323.79 (+0.82%)
ALXN : 128.80 (+0.98%)
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

IBB : 110.33 (+1.08%)
FBT : 143.92 (+0.92%)
BBH : 127.23 (+0.95%)
GILD : 65.56 (+0.02%)
AMGN : 186.94 (+0.78%)
BIIB : 323.79 (+0.82%)
ALXN : 128.80 (+0.98%)
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T

The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T

BBT : 51.53 (-0.58%)
V : 145.63 (+1.13%)
CHTR : 349.70 (+0.05%)
BP : 42.46 (+0.40%)
BIIB : 323.79 (+0.82%)
Top Research Reports for Visa, Charter Communications & Biogen

Top Research Reports for Visa, Charter Communications & Biogen

BBT : 51.53 (-0.58%)
V : 145.63 (+1.13%)
RHHBY : 34.6700 (+0.33%)
CHTR : 349.70 (+0.05%)
BP : 42.46 (+0.40%)
BIIB : 323.79 (+0.82%)
Alkermes Sinks as FDA Refuses to Approve Depression Drug

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

GALT : 5.69 (-5.48%)
AZN : 40.82 (+0.96%)
ALKS : 33.16 (+1.81%)
BIIB : 323.79 (+0.82%)
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.

JNJ : 136.42 (+0.74%)
ABBV : 79.77 (+1.30%)
RHHBY : 34.6700 (+0.33%)
BIIB : 323.79 (+0.82%)
Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4

Biogen (BIIB) beat estimates both for earnings and sales in Q4. Its newest drug Spinraza performed well in the quarter.

BIIB : 323.79 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 335.45
1st Resistance Point 328.31
Last Price 323.79
1st Support Level 317.21
2nd Support Level 313.25

See More

52-Week High 388.67
Fibonacci 61.8% 335.38
Last Price 323.79
Fibonacci 50% 318.92
Fibonacci 38.2% 302.46
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar